Azithromycin for improving pulmonary function in cystic fibrosis |
| |
Authors: | Carr Roxane R Nahata Milap C |
| |
Institution: | College of Pharmacy, Ohio State University, Columbus, OH 43210-1291, USA. |
| |
Abstract: | OBJECTIVE: To review the literature concerning the use of azithromycin in the treatment of patients with cystic fibrosis (CF). DATA SOURCES: A search of MEDLINE (1966-April 2004), Embase (1980-April 2004), and International Pharmaceutical Abstracts (1971-April 2004) was performed. Search terms included cystic fibrosis, macrolide, and azithromycin. DATA SYNTHESIS: Four studies have been performed in 7-185 patients (children and adults) over a 3- to 6-month period. The azithromycin dosage ranged from 250 mg 3 times weekly to 500 mg daily. The trials reported an improvement in percent predicted forced expiratory volume ranging from 2.95% to 6.2% in patients treated with azithromycin compared with those receiving placebo. CONCLUSIONS: Azithromycin appeared to improve pulmonary function in adults and older children with CF and was well tolerated when administered for 6 months. Further research is needed to determine an optimal dosage regimen, duration of treatment, effects on quality of life, and cost-effectiveness of azithromycin therapy. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|